Nostics

Executive Summary

Nostics, founded in 2020 and headquartered in Leiden, Netherlands, is a pioneering diagnostics company developing ultra-rapid point-of-care infection tests. Its proprietary platform leverages real-time spectral analysis of living pathogens directly from patient samples, delivering results in under 10 minutes. This technology aims to address the critical need for rapid, accurate diagnostics to combat antimicrobial resistance by enabling personalized, data-driven antibiotic prescriptions. By shifting diagnostics from centralized labs to the point of need, Nostics has the potential to significantly improve clinical outcomes and reduce healthcare costs, particularly in emergency and primary care settings where timely treatment decisions are crucial. The company's focus on speed and simplicity positions it as a disruptive player in the global infectious disease diagnostics market, which is projected to grow substantially as antimicrobial resistance becomes a top public health priority.

Upcoming Catalysts (preview)

• Q3 2026Initial Clinical Validation Results60% success
• Q4 2026CE Mark Certification for First Product50% success
• Q2 2026Strategic Funding or Partnership Announcement70% success